pf-06260414
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02070939)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CNS(=O)(=O)N(c2ccc3c(C#N)nccc3c2)C1- Mol. weight
- 302.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297476 ↗
Also known as
- pf-06260414
- pf-06260414
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02393807 | Phase 1 | Jun 1, 2015 | Pfizer |
| NCT02070939 | Phase 1 | Feb 1, 2014 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2014 |
1 organizations
Page 1 / 1